Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, March 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 195 articles:
HTML format


 

Single Articles

  1. DO NASCIMENTO ALVES SIPM, Lavalhegas Hallack M, Moreira Perez M, da Costa Aguiar Alves B, et al
    Application of the Z-scan technique for the detection of CFCDNA (cell-free circulating DNA) and urine DNA (uDNA) in patients with bladder cancer.
    Photodiagnosis Photodyn Ther. 2019 Feb 26. pii: S1572-1000(18)30338.
    Abstract    



  2. JIANG G, Huang C, Liao X, Li J, et al
    The RING domain in the anti-apoptotic protein XIAP stabilizes c-Myc protein and preserves anchorage-independent growth of bladder cancer cells.
    J Biol Chem. 2019 Feb 28. pii: RA118.005621. doi: 10.1074/jbc.RA118.005621.
    Abstract    

    Abstract available

  3. LIN JJ, Huang CC, Su YL, Luo HL, et al
    Proteomics Analysis of Tangeretin-Induced Apoptosis through Mitochondrial Dysfunction in Bladder Cancer Cells.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  4. WU T, Duan X, Hu C, Wu C, et al
    Synthesis and characterization of gold nanoparticles from Abies spectabilis extract and its anticancer activity on bladder cancer T24 cells.
    Artif Cells Nanomed Biotechnol. 2019;47:512-523.
    Abstract    

    Abstract available

  5. LAZARO M, Gallardo E, Domenech M, Pinto A, et al
    Correction to: SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).
    Clin Transl Oncol. 2019 Feb 26. pii: 10.1007/s12094-019-02061.
    Abstract    

    Abstract available

  6. MATULAY JT, Narayan VM, Kamat AM
    Clinical and Genomic Considerations for Variant Histology in Bladder Cancer.
    Curr Oncol Rep. 2019;21:23.
    Abstract    

    Abstract available

  7. CHOI JB, Kim JH, Hong SH, Han KD, et al
    Association of body mass index with bladder cancer risk in men depends on abdominal obesity.
    World J Urol. 2019 Feb 26. pii: 10.1007/s00345-019-02690.
    Abstract    

    Abstract available

  8. LIN JH, Chen SJ, Liu H, Yan Y, et al
    Vitamin E consumption and the risk of bladder cancer.
    Int J Vitam Nutr Res. 2019 Feb 26:1-8. doi: 10.1024/0300-9831/a000553.
    Abstract    

    Abstract available

  9. TURKER P, Segersten U, Malmstrom PU, Hemdan T, et al
    Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
    Scand J Urol. 2019 Feb 26:1-6. doi: 10.1080/21681805.2019.1575467.
    Abstract    

    Abstract available

  10. DATOVO JCF, Neto WA, Mendonca GB, Andrade DL, et al
    Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC).
    World J Urol. 2019 Feb 25. pii: 10.1007/s00345-019-02697.
    Abstract    

    Abstract available

  11. BOERI L, Soligo M, Frank I, Boorjian SA, et al
    Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.
    World J Urol. 2019 Feb 25. pii: 10.1007/s00345-019-02689.
    Abstract    

    Abstract available

  12. GURUNG PMS, Barnett AR, Wilson JS, Hudson J, et al
    Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
    Eur Urol Focus. 2019 Feb 22. pii: S2405-4569(19)30032.
    Abstract    

    Abstract available

  13. CHIANG CH, Chung JG, Hsu FT
    Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-kappaB-modulated tumor progression in bladder cancer in vitro and in vivo.
    Environ Toxicol. 2019 Feb 25. doi: 10.1002/tox.22734.
    Abstract    

    Abstract available

  14. MEHTALA J, Khanfir H, Bennett D, Ye Y, et al
    Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies.
    Diabetol Int. 2018;10:24-36.
    Abstract    

    Abstract available

  15. POLETAJEW S, Fus L, Ilczuk T, Wojcieszak P, et al
    Expression of E-cadherin, beta-catenin, and epithelial membrane antigen does not predict survival in patients with high-risk non-muscle-invasive bladder cancer.
    Cent Eur J Immunol. 2018;43:421-427.
    Abstract    

    Abstract available

  16. BALAKRISHNAN AS, Washington SL 3rd, Meng MV, Porten SP, et al
    Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.
    Clin Genitourin Cancer. 2019 Jan 19. pii: S1558-7673(19)30018.
    Abstract    

    Abstract available

  17. LI Y, Rapkin B, Atkinson TM, Schofield E, et al
    Leveraging Latent Dirichlet Allocation in processing free-text personal goals among patients undergoing bladder cancer surgery.
    Qual Life Res. 2019 Feb 23. pii: 10.1007/s11136-019-02132.
    Abstract    

    Abstract available

  18. SATHIANATHEN NJ, Fan Y, Jarosek SL, Konety I, et al
    Disparities in Bladder Cancer Treatment and Survival Amongst Elderly Patients with a Pre-existing Mental Illness.
    Eur Urol Focus. 2019 Feb 20. pii: S2405-4569(19)30027.
    Abstract    

    Abstract available

  19. SHIMIZU N, Hamaide A, Dourcy M, Noel S, et al
    Evaluation of urinary and serum level of chemokine (C-C motif) ligand 2 as a potential biomarker in canine urothelial tumours.
    Vet Comp Oncol. 2019;17:11-20.
    Abstract    

    Abstract available

  20. AHSAINI M, Ouattar K, Azelmad H, Mellas S, et al
    A rare pure embryonal rhabdomyosarcoma of the urinary bladder in an adult successfully managed with neoadjuvant chemotherapy and surgery: a case report.
    J Med Case Rep. 2018;12:329.
    Abstract    

    Abstract available

  21. TALAT Z, Onal B, Cetinel B, Demirdag C, et al
    The surgical technique and initial outcomes of Anatolian neobladder: a novel technique of ileal neobladder after radical cystectomy.
    BMC Urol. 2018;18:94.
    Abstract    

    Abstract available

  22. JIN L, Wang M, Yang F, Niu Y, et al
    Surgical techniques for facilitating laparoscopic intracorporeal orthotopic neobladder: initial experience.
    Int Braz J Urol. 2018;44:1156-1165.
    Abstract    

    Abstract available

  23. FOGAZZI GB, Delanghe J
    Microscopic examination of urine sediment: Phase contrast versus bright field.
    Clin Chim Acta. 2018;487:168-173.
    Abstract    

    Abstract available

  24. KALETSCH A, Pinkerneil M, Hoffmann MJ, Jaguva Vasudevan AA, et al
    Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Clin Epigenetics. 2018;10:100.
    Abstract    

    Abstract available

  25. FIELDER S, Breshears M
    What is your diagnosis? Bladder mass in a mare.
    Vet Clin Pathol. 2018;47:665-666.
    Abstract    



  26. FERSINO S, Arcangeli S, Jereczek-Fossa BA, D'Angelillo R, et al
    GUROPA survey: genito-urinary radiation oncology prescription attitudes.
    Radiol Med. 2018;123:879-884.
    Abstract    

    Abstract available

  27. JOHANSSON S, Walters R, Mayer K, Shippey S, et al
    Vaginal Myomectomy to Resolve Bladder Outlet Obstruction 50 Years After Hysterectomy.
    Female Pelvic Med Reconstr Surg. 2018;24:e26-e28.
    Abstract    

    Abstract available

  28. HORI S, Mitsui Y, Suzuki K, Nakajima K, et al
    [Penile Metastasis from Invasive Bladder Carcinoma Diagnosed by Needle Biopsy : A Case Report and Literature Review].
    Hinyokika Kiyo. 2018;64:127-130.
    Abstract    

    Abstract available

  29. UCHIDA M, Kawai K, Kurobe M, Ikeda A, et al
    [Metastases of Urothelial Carcinoma with Trophoblastic Differentiation that Responded to Combination Chemotherapy with Gemcitabine and Oxaliplatin : A Case Report].
    Hinyokika Kiyo. 2018;64:55-61.
    Abstract    

    Abstract available

  30. BRETSCHNEIDER CE, Share SM, Paraiso MFR
    Nephrogenic Adenoma in the Setting of Refractory Labial Agglutination in an Elderly Woman.
    Female Pelvic Med Reconstr Surg. 2018;24:e6-e8.
    Abstract    

    Abstract available

  31. SANFORD T, Meng MV, Railkar R, Agarwal PK, et al
    Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.
    Clin Epigenetics. 2018;10:19.
    Abstract    

    Abstract available

  32. BOTELHO F
    Editorial Comment on: Isolated Red Patches Seen During Endoscopic Surveillance of Bladder Cancer: Incidence of Malignancy and When Should We Biopsy? by Nkwam et al.
    J Endourol. 2018;32:328.
    Abstract    



  33. HOLSCHER AS, Schulz WA, Pinkerneil M, Niegisch G, et al
    Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
    Clin Epigenetics. 2018;10:1.
    Abstract    

    Abstract available

  34. FERNANDEZ-ACENERO MJ, Perez Alonso P, Diaz Del Arco C
    Histiocytic sarcoma with bladder involvement: Case report and literature review.
    Rev Esp Patol. 2018;51:23-26.
    Abstract    

    Abstract available

  35. HUANG SY, Chien CC, Hseu RS, Huang VYJ, et al
    Ganoderma microsporum immunomodulatory protein induces apoptosis and potentiates mitomycin C-induced apoptosis in urinary bladder urothelial carcinoma cells.
    J Cell Biochem. 2018;119:4592-4606.
    Abstract    

    Abstract available

  36. SMITH AH, Marshall G, Roh T, Ferreccio C, et al
    Lung, Bladder, and Kidney Cancer Mortality 40 Years After Arsenic Exposure Reduction.
    J Natl Cancer Inst. 2018;110:241-249.
    Abstract    

    Abstract available

  37. AFSHARPAD M, Nowroozi MR, Mobasheri MB, Ayati M, et al
    Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder.
    Pathol Oncol Res. 2019;25:191-199.
    Abstract    

    Abstract available

  38. MOSCHINI M, Morlacco A, Briganti A, Hu B, et al
    Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy.
    Eur Urol Focus. 2018;4:245-251.
    Abstract    

    Abstract available

  39. VETTERLEIN MW, Seisen T, May M, Nuhn P, et al
    Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    Eur Urol Focus. 2018;4:252-259.
    Abstract    

    Abstract available

  40. JOSHI M, Millis SZ, Arguello D, Holder SL, et al
    Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers.
    Eur Urol Focus. 2018;4:94-97.
    Abstract    

    Abstract available

  41. COLOMBO R, Hurle R, Moschini M, Freschi M, et al
    Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer.
    Eur Urol Focus. 2018;4:87-93.
    Abstract    

    Abstract available

  42. OKUBO K, Isono M, Asano T, Sato A, et al
    Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase.
    Transl Oncol. 2019;12:669-682.
    Abstract    

    Abstract available

  43. SONG Y, Yang Y, Liu L, Liu X, et al
    Association between five polymorphisms in vascular endothelial growth factor gene and urinary bladder cancer risk: A systematic review and meta-analysis involving 6671 subjects.
    Gene. 2019 Mar 5. pii: S0378-1119(19)30211-2. doi: 10.1016/j.gene.2019.
    Abstract    

    Abstract available

  44. ZHANG W, Shi L, Zhao Z, Du P, et al
    Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.
    Cancer Chemother Pharmacol. 2019 Mar 8. pii: 10.1007/s00280-019-03800.
    Abstract    

    Abstract available

  45. HOU T, Zhou L, Wang L, Kazobinka G, et al
    Correction: CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway.
    Oncotarget. 2019;10:1010.
    Abstract    

    Abstract available

  46. FAN J, Wu K, Zhang P, He D, et al
    Green-laser assisted laparoscopic partial cystectomy for selective muscle-invasive bladder cancer: technique and initial outcome.
    World J Urol. 2019 Mar 6. pii: 10.1007/s00345-019-02712.
    Abstract    

    Abstract available

  47. KONALA VM, Adapa S, Aronow WS
    Immunotherapy in Bladder Cancer.
    Am J Ther. 2019 Feb 28. doi: 10.1097/MJT.0000000000000934.
    Abstract    

    Abstract available

  48. GOK B, Atmaca AF, Canda AE, Asil E, et al
    Robotic radical cystectomy with intracorporeal Studer pouch formation for bladder cancer: Experience in 98 cases.
    J Endourol. 2019 Mar 6. doi: 10.1089/end.2019.0036.
    Abstract    

    Abstract available

  49. KIM DK, Lee JY, Jung JH, Hah YS, et al
    Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials.
    Investig Clin Urol. 2019;60:64-74.
    Abstract    

    Abstract available

  50. GILD P, Nguyen DD, Fletcher SA, Cole AP, et al
    Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy.
    Clin Genitourin Cancer. 2019 Jan 29. pii: S1558-7673(19)30036.
    Abstract    

    Abstract available

  51. TEMRAZ S, Haibe Y, Charafeddine M, Saifi O, et al
    The unveiling of a new risk factor associated with bladder cancer in Lebanon.
    BMC Urol. 2019;19:16.
    Abstract    

    Abstract available

  52. HUMAYUN-ZAKARIA N, Arnold R, Goel A, Ward D, et al
    Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  53. BABJUK M
    En-bloc resection of non-muscle invasive bladder cancer: what must be answered in the future?
    World J Urol. 2019 Mar 5. pii: 10.1007/s00345-019-02710.
    Abstract    



  54. RODRIGUES D, Pinto J, Araujo AM, Monteiro-Reis S, et al
    Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry.
    Metabolomics. 2018;14:62.
    Abstract    

    Abstract available

  55. LIANG H, Yang T, Wu K, He D, et al
    En bloc resection improves the identification of muscularis mucosae in non-muscle invasive bladder cancer.
    World J Urol. 2019 Mar 4. pii: 10.1007/s00345-019-02672.
    Abstract    

    Abstract available

  56. SAWICKA E, Kratz EM, Szymanska B, Guzik A, et al
    Preliminary Study on Selected Markers of Oxidative Stress, Inflammation and Angiogenesis in Patients with Bladder Cancer.
    Pathol Oncol Res. 2019 Mar 4. pii: 10.1007/s12253-019-00620.
    Abstract    

    Abstract available

  57. WANG J, Zhang J, Li T, Shen R, et al
    Strand displacement amplification-coupled dynamic light scattering method to detect urinary telomerase for non-invasive detection of bladder cancer.
    Biosens Bioelectron. 2019;131:143-148.
    Abstract    

    Abstract available

  58. HUANG C, Liao X, Jin H, Xie F, et al
    MEG3, as a Competing Endogenous RNA, Binds with miR-27a to Promote PHLPP2 Protein Translation and Impairs Bladder Cancer Invasion.
    Mol Ther Nucleic Acids. 2019;16:51-62.
    Abstract    

    Abstract available

  59. LINDNER AK, Klatte T, Comperat E, Heidegger I, et al
    Therapeutic rationale of targeting BCG and immune checkpoints in non-muscle-invasive bladder cancer: Is this the Future?
    Urol Oncol. 2019 Feb 27. pii: S1078-1439(19)30054.
    Abstract    



  60. GIRARD A, Rouanne M
    Comment on: Relationship between the expression of PD-1/PD-L1 and (18)F-FDG uptake in bladder cancer.
    Eur J Nucl Med Mol Imaging. 2019 Mar 1. pii: 10.1007/s00259-019-04296.
    Abstract    



  61. BERNDT-PAETZ M, Schulze P, Stenglein PC, Weimann A, et al
    Reduction of muscle-invasive tumors by photodynamic therapy with Tetrahydroporphyrin-Tetratosylat in an orthotopic rat bladder cancer model.
    Mol Cancer Ther. 2019 Mar 1. pii: 1535-7163.MCT-18-1194.
    Abstract    

    Abstract available

  62. GAO R, Zhang N, Yang J, Zhu Y, et al
    Long non-coding RNA ZEB1-AS1 regulates miR-200b/FSCN1 signaling and enhances migration and invasion induced by TGF-beta1 in bladder cancer cells.
    J Exp Clin Cancer Res. 2019;38:111.
    Abstract    

    Abstract available

  63. MA Y, Mao G, Zhong Y, Wu G, et al
    Highly sensitive ratiometric fluorescent paper sensor for the urine assay of cancer.
    Talanta. 2019;194:199-204.
    Abstract    

    Abstract available

  64. MITRA AP, Fairey AS, Skinner EC, Boorjian SA, et al
    Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation.
    Urol Oncol. 2019;37:48-56.
    Abstract    

    Abstract available

  65. SASAHARA T, Sasaki H, Yoshiyama Y, Kimura S, et al
    [A Case of Urachal Carcinoma Treated with Laparoscopic Resection of Urachal Remnants with Partial Cystectomy that was Difficult to Diagnose Preoperatively by Transurethral Biopsy].
    Hinyokika Kiyo. 2018;64:345-348.
    Abstract    

    Abstract available

  66. BARNES JL, Zubair M, John K, Poirier MC, et al
    Carcinogens and DNA damage.
    Biochem Soc Trans. 2018;46:1213-1224.
    Abstract    

    Abstract available

  67. PAI A, Mackie S, Watson G
    Novel use of air in laser ablation of bladder transitional cell carcinoma.
    Ann R Coll Surg Engl. 2019;101:227.
    Abstract    



  68. DENIZE J, Bugel H, Bou Nasr E, Delcourt C, et al

    Gynecol Obstet Fertil Senol. 2018;46.
    Abstract    



  69. QIN ZJ, Bi H, Ma LL, Huang Y, et al
    [A primary intestinal-derived adenocarcinoma in intestine bladder substitutes: a case report].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2018;50:737-739.
    Abstract    

    Abstract available

  70. TANG XG, Yan Y, Qiu M, Lu J, et al
    [Retrospective study of young bladder urothelial carcinoma from a single center within 16 years].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2018;50:630-633.
    Abstract    

    Abstract available

  71. AKHTAR S, Al-Shammari A, Al-Abkal J
    Chronic urinary tract infection and bladder carcinoma risk: a meta-analysis of case-control and cohort studies.
    World J Urol. 2018 Feb 5. pii: 10.1007/s00345-018-2206.
    Abstract    

    Abstract available

  72. KIM BS, Tae BS, Ku JH, Kwak C, et al
    Rate and association of lower urinary tract infection with recurrence after transurethral resection of bladder tumor.
    Investig Clin Urol. 2018;59:10-17.
    Abstract    

    Abstract available

  73. CENCINI E, Fabbri A, Schiattone L, Gentili F, et al
    Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma.
    Acta Clin Belg. 2018;73:408-412.
    Abstract    

    Abstract available

  74. INOUE S, Mizushima T, Miyamoto H
    Role of the androgen receptor in urothelial cancer.
    Mol Cell Endocrinol. 2018;465:73-81.
    Abstract    

    Abstract available

  75. GIANNOPOULOU AF, Velentzas AD, Konstantakou EG, Avgeris M, et al
    Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  76. STEELE TM, Talbott GC, Sam A, Tepper CG, et al
    Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  77. LUNDBERG E, Hagberg O, Jahnson S, Ljungberg B, et al
    Association between occurrence of urinary bladder cancer and treatment with statin medication.
    Turk J Urol. 2019;45:97-102.
    Abstract    

    Abstract available

  78. HAIDER M, Ladurner C, Mayr R, Tandogdu Z, et al
    Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series.
    Urol Oncol. 2019 Mar 12. pii: S1078-1439(19)30018.
    Abstract    

    Abstract available

  79. ZHU J, Li Y, Luo Y, Xu J, et al
    A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-Like Properties and Invasion in Human Bladder Cancer.
    Cancers (Basel). 2019;11.
    Abstract    

    Abstract available

  80. POLETAJEW S, Krajewski W, Adamowicz J, Radziszewski P, et al
    A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette-Guerin immunotherapy.
    Anticancer Drugs. 2019 Mar 11. doi: 10.1097/CAD.0000000000000775.
    Abstract    

    Abstract available

  81. BAI ZJ, Liu Q, Wang XS, Liu WY, et al
    APC promoter methylation is correlated with development and progression of bladder cancer, but not linked to overall survival: a meta-analysis.
    Neoplasma. 2019 Mar 7. pii: 181009N753. doi: 10.4149/neo_2018_181009.
    Abstract    

    Abstract available

  82. CHEN J, Cao L, Li Z, Li Y, et al
    SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake.
    Hum Cell. 2019 Mar 13. pii: 10.1007/s13577-019-00237.
    Abstract    

    Abstract available

  83. CADIOU S, Al Tabaa O, Nguyen CD, Faccin M, et al
    Back pain following instillations of BCG for superficial bladder cancer is not a reactive complication: review of 30 Mycobacterium bovis BCG vertebral osteomyelitis cases.
    Clin Rheumatol. 2019 Mar 13. pii: 10.1007/s10067-019-04500.
    Abstract    

    Abstract available

  84. PHILLIPS RM, Loadman PM, Reddy G
    Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer.
    Cancer Chemother Pharmacol. 2019 Mar 13. pii: 10.1007/s00280-019-03812.
    Abstract    

    Abstract available

  85. WEN W, Gong J, Wu P, Zhao M, et al
    Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis.
    FEBS Open Bio. 2019;9:457-467.
    Abstract    

    Abstract available

  86. LIN G, Sheng H, Xie H, Zheng Q, et al
    circLPAR1 is a novel biomarker of prognosis for muscle-invasive bladder cancer with invasion and metastasis by miR-762.
    Oncol Lett. 2019;17:3537-3547.
    Abstract    

    Abstract available

  87. ALBERTO M, Cuello HA, Gulino CA, Pifano M, et al
    Expression of bladder cancer-associated glycans in murine tumor cell lines.
    Oncol Lett. 2019;17:3141-3150.
    Abstract    

    Abstract available

  88. WANG Z, Zhou Q, Li A, Huang W, et al
    Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer.
    Onco Targets Ther. 2019;12:1423-1432.
    Abstract    

    Abstract available

  89. YANG Y, Wang F, Huang H, Zhang Y, et al
    lncRNA SLCO4A1-AS1 promotes growth and invasion of bladder cancer through sponging miR-335-5p to upregulate OCT4.
    Onco Targets Ther. 2019;12:1351-1358.
    Abstract    

    Abstract available

  90. SUO N, Wang M, Jin Y, Ding J, et al
    Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer.
    Int J Nanomedicine. 2019;14:1241-1254.
    Abstract    

    Abstract available

  91. KLAASSEN Z, Lokeshwar SD, Lowery-Allison A, Wallis CJD, et al
    Mental Illness and Bladder Cancer Patients: The Time for Assertive Intervention Is Now.
    Eur Urol Focus. 2019 Mar 9. pii: S2405-4569(19)30075.
    Abstract    



  92. LIM CS, Tirumani S, van der Pol CB, Alessandrino F, et al
    Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection.
    AJR Am J Roentgenol. 2019 Mar 12:1-10. doi: 10.2214/AJR.18.20718.
    Abstract    

    Abstract available

  93. JOSHUA JM, Vijayan M, Pooleri GK
    A retrospective analysis of patients treated with intravesical BCG for high-risk nonmuscle invasive bladder cancer.
    Ther Adv Urol. 2019;11:1756287219833056.
    Abstract    

    Abstract available

  94. WANG F, Wu D, Xu Z, Chen J, et al
    miR-182-5p affects human bladder cancer cell proliferation, migration and invasion through regulating Cofilin 1.
    Cancer Cell Int. 2019;19:42.
    Abstract    

    Abstract available

  95. OUYANG XL, Yang L, Huang L, Pan YM, et al
    Antitumor activity on human bladder cancer T-24 cells and composition analysis of the core of Camellia osmantha fruit.
    Nat Prod Res. 2019 Mar 11:1-5. doi: 10.1080/14786419.2018.1550763.
    Abstract    

    Abstract available

  96. WU E, Hadjiiski LM, Samala RK, Chan HP, et al
    Deep Learning Approach for Assessment of Bladder Cancer Treatment Response.
    Tomography. 2019;5:201-208.
    Abstract    

    Abstract available

  97. CHAND D, Dhawan D, Sankin A, Ren X, et al
    Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.
    Bladder Cancer. 2019;5:63-71.
    Abstract    

    Abstract available

  98. LIU NW, Murray KS, Donat SM, Herr HW, et al
    The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum.
    Bladder Cancer. 2019;5:13-19.
    Abstract    

    Abstract available

  99. AQUILA L, Ohm J, Woloszynska-Read A
    Corrigendum to "The role of STAG2 in bladder cancer" [Pharmacol. Res. 131 (2018) 143-149].
    Pharmacol Res. 2019 Mar 7. pii: S1043-6618(19)30336.
    Abstract    



  100. BOORMANS JL, Zwarthoff EC, Black PC, Goebell PJ, et al
    New horizons in bladder cancer research.
    Urol Oncol. 2019 Mar 7. pii: S1078-1439(18)30508.
    Abstract    

    Abstract available

  101. MARKS P, Gild P, Soave A, Janisch F, et al
    The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy.
    Surg Oncol. 2019;28:208-213.
    Abstract    

    Abstract available

  102. LI R, Zhang L, Qin Z, Wei Y, et al
    High LINC00536 expression promotes tumor progression and poor prognosis in bladder cancer.
    Exp Cell Res. 2019 Mar 6. pii: S0014-4827(19)30103.
    Abstract    

    Abstract available

  103. BRANT A, Daniels M, Chappidi MR, Joice GA, et al
    Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.
    World J Urol. 2019 Mar 8. pii: 10.1007/s00345-019-02673.
    Abstract    

    Abstract available

  104. MOSCHINI M, Martini A, Zamboni S, Mattei A, et al
    Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery.
    Clin Genitourin Cancer. 2019 Feb 13. pii: S1558-7673(19)30045.
    Abstract    

    Abstract available

  105. SILVERDALE N, Wherry M, Roodhouse A
    Massage and reflexology for post-operative cancer cystectomy patients: Evaluation of a pilot service.
    Complement Ther Clin Pract. 2019;34:109-112.
    Abstract    

    Abstract available

  106. KIM SC, Park S, Song SH, Kim KS, et al
    Clinicopathological Characteristics of Urinary Bladder Tumors in Korean Patients 20 Years or Younger.
    J Korean Med Sci. 2018;33:e242.
    Abstract    

    Abstract available

  107. LI P, Ning J, Luo X, Du H, et al
    New method to preserve the original proportion and integrity of urinary cell-free DNA.
    J Clin Lab Anal. 2019;33:e22668.
    Abstract    

    Abstract available

  108. GE Y, Zhu J, Wang X, Zheng N, et al
    Mapping dynamic histone modification patterns during arsenic-induced malignant transformation of human bladder cells.
    Toxicol Appl Pharmacol. 2018;355:164-173.
    Abstract    

    Abstract available

  109. SILLS WS, Howerth EW
    Pathology in Practice.
    J Am Vet Med Assoc. 2018;252:1063-1066.
    Abstract    



  110. LOERTZER P, Siemer S, Stockle M, Ohlmann CH, et al
    Robot-sewn ileoileal anastomosis during robot-assisted cystectomy.
    World J Urol. 2018;36:1079-1084.
    Abstract    

    Abstract available

  111. HA YS, Kim SW, Kwon TG, Chung SK, et al
    Decrease in skeletal muscle index 1 year after radical cystectomy as a prognostic indicator in patients with urothelial bladder cancer.
    Int Braz J Urol. 2019;45.
    Abstract    

    Abstract available

  112. LIAN F, Chen W, Liu Y, Shen L, et al
    Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
    J Cancer Res Clin Oncol. 2019 Mar 21. pii: 10.1007/s00432-019-02900.
    Abstract    

    Abstract available

  113. FU S, Luan T, Jiang C, Huang Y, et al
    miR-3622a promotes proliferation and invasion of bladder cancer cells by downregulating LASS2.
    Gene. 2019 Mar 18. pii: S0378-1119(19)30247-1. doi: 10.1016/j.gene.2019.
    Abstract    

    Abstract available

  114. CHEN J, Song B, Kong G
    MicroRNA663b downregulation inhibits proliferation and induces apoptosis in bladder cancer cells by targeting TUSC2.
    Mol Med Rep. 2019 Mar 14. doi: 10.3892/mmr.2019.10023.
    Abstract    

    Abstract available

  115. BABJUK M
    En-bloc resection of non-muscle invasive bladder cancer: what must be answered in the future?
    World J Urol. 2019 Mar 20. pii: 10.1007/s00345-019-02715.
    Abstract    



  116. GUPTA M, Kates M, Bivalacqua TJ
    Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.
    Curr Opin Oncol. 2019 Mar 15. doi: 10.1097/CCO.0000000000000533.
    Abstract    

    Abstract available

  117. AL KHADER AM, Abu Shahin NI, Obeidat FN, Al-Chalabi MA, et al
    Urinary bladder cancer in Jordanian adults: A histopathological and epidemiological study from a tertiary care center in Amman.
    J Pak Med Assoc. 2019;69:415-417.
    Abstract    

    Abstract available

  118. YAJIMA S, Yoshida S, Takahara T, Arita Y, et al
    Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression.
    Eur Radiol. 2019 Mar 19. pii: 10.1007/s00330-019-06119.
    Abstract    

    Abstract available

  119. HAN Y, Zheng Q, Tian Y, Ji Z, et al
    Identification of a nine-gene panel as a prognostic indicator for recurrence with muscle-invasive bladder cancer.
    J Surg Oncol. 2019 Mar 18. doi: 10.1002/jso.25446.
    Abstract    

    Abstract available

  120. WALKER AK, Karaszi K, Valentine H, Strauss VY, et al
    MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer.
    Int J Radiat Oncol Biol Phys. 2019 Mar 15. pii: S0360-3016(19)30371.
    Abstract    

    Abstract available

  121. SHAKIBAIE M, Vaezjalali M, Rafii-Tabar H, Sasanpour P, et al
    Synergistic effect of phototherapy and chemotherapy on bladder cancer cells.
    J Photochem Photobiol B. 2019;193:148-154.
    Abstract    

    Abstract available

  122. AMIR H, Khan MA, Feroz S, Bibi N, et al
    CARLo-7-A plausible biomarker for bladder cancer.
    Int J Exp Pathol. 2019 Mar 18. doi: 10.1111/iep.12305.
    Abstract    

    Abstract available

  123. HUANG D, Jin YH, Weng H, Huang Q, et al
    Combination of Intravesical Bacille Calmette-Guerin and Chemotherapy vs. Bacille Calmette-Guerin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis.
    Front Oncol. 2019;9:121.
    Abstract    

    Abstract available

  124. MA J, Sun G, Zhu P, Liu S, et al
    Determination of the complexity and diversity of the TCR beta-chain CDR3 repertoire in bladder cancer using high-throughput sequencing.
    Oncol Lett. 2019;17:3808-3816.
    Abstract    

    Abstract available

  125. ZHAO H, Bo Q, Wu Z, Liu Q, et al
    KIF15 promotes bladder cancer proliferation via the MEK-ERK signaling pathway.
    Cancer Manag Res. 2019;11:1857-1868.
    Abstract    

    Abstract available

  126. FAN Z, Liang Y, Yang X, Li B, et al
    A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer.
    Onco Targets Ther. 2019;12:1791-1801.
    Abstract    

    Abstract available

  127. LEKKA M, Pabijan J, Orzechowska B
    Morphological and mechanical stability of bladder cancer cells in response to substrate rigidity.
    Biochim Biophys Acta Gen Subj. 2019 Mar 13. pii: S0304-4165(19)30060.
    Abstract    

    Abstract available

  128. LARCHER A, Gandaglia G, Wiklund P, Mottrie A, et al
    Robot-assisted versus open cystectomy in the RAZOR trial.
    Lancet. 2019;393:645.
    Abstract    



  129. PAREKH DJ, Venkatramani V
    Robot-assisted versus open cystectomy in the RAZOR trial - Authors' reply.
    Lancet. 2019;393:645-646.
    Abstract    



  130. KHETRAPAL P, Catto JWF, Kelly JD
    Robot-assisted versus open cystectomy in the RAZOR trial.
    Lancet. 2019;393:644-645.
    Abstract    



  131. DAL MORO F
    Tomorrow (and surgery) never dies.
    Lancet. 2019;393:642-644.
    Abstract    



  132. ROCHEL N, Krucker C, Coutos-Thevenot L, Osz J, et al
    Recurrent activating mutations of PPARgamma associated with luminal bladder tumors.
    Nat Commun. 2019;10:253.
    Abstract    

    Abstract available

  133. ERBEN P, Sikic D, Wirtz RM, Martini T, et al
    Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.
    Virchows Arch. 2019;474:209-217.
    Abstract    

    Abstract available

  134. ALTUN E
    MR Imaging of the Urinary Bladder: Added Value of PET-MR Imaging.
    Magn Reson Imaging Clin N Am. 2019;27:105-115.
    Abstract    

    Abstract available

  135. CHEN YT, Yang CC, Shao PL, Huang CR, et al
    Melatonin-mediated downregulation of ZNF746 suppresses bladder tumorigenesis mainly through inhibiting the AKT-MMP-9 signaling pathway.
    J Pineal Res. 2019;66:e12536.
    Abstract    

    Abstract available

  136. HAN YS, Kim SM, Lee JH, Jung SK, et al
    Melatonin protects chronic kidney disease mesenchymal stem cells against senescence via PrP(C) -dependent enhancement of the mitochondrial function.
    J Pineal Res. 2019;66:e12535.
    Abstract    

    Abstract available

  137. AGGARWAL A, Agarwal S, Pandey S, Sankhwar S, et al
    Urachal adenocarcinoma.
    BMJ Case Rep. 2018;2018.
    Abstract    



  138. HODGSON A, Liu SK, Vesprini D, Xu B, et al
    Basal-subtype bladder tumours show a 'hot' immunophenotype.
    Histopathology. 2018;73:748-757.
    Abstract    

    Abstract available

  139. ANDRES-LENCINA JJ, Burillo-Martinez S, Aragon-Miguel R, Calleja-Algarra A, et al
    Eosinophilic fasciitis and lichen sclerosus in a patient treated with nivolumab.
    Australas J Dermatol. 2018;59:e302-e304.
    Abstract    



  140. BRIMO F, Downes MR, Jamaspishvili T, Berman D, et al
    Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy.
    Histopathology. 2018;73:732-740.
    Abstract    

    Abstract available

  141. DELLABELLA M, Branchi A, Gasparri L, Claudini R, et al
    Oncological safety and quality of life in men undergoing simultaneous transurethral resection of bladder tumor and prostate: results from a randomized controlled trial.
    World J Urol. 2018;36:1629-1634.
    Abstract    

    Abstract available

  142. TAYLOR JM, McTyre ER, Tatter SB, Laxton AW, et al
    Gamma Knife Stereotactic Radiosurgery for the Treatment of Brain Metastases from Primary Tumors of the Urinary Bladder.
    Stereotact Funct Neurosurg. 2018;96:108-112.
    Abstract    

    Abstract available

  143. VASYUTIN I, Zerihun L, Ivan C, Atala A, et al
    Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling.
    Anticancer Res. 2019;39:1105-1118.
    Abstract    

    Abstract available

  144. KUMAGAI-TOGASHI A, Uozaki H, Kikuchi Y, Watabe S, et al
    Tumorous CD10 Is More Strongly Related to the Progression of Urothelial Carcinoma than Stromal CD10.
    Anticancer Res. 2019;39:635-640.
    Abstract    

    Abstract available

  145. KIJIMA T, Tanaka H, Koga F, Masuda H, et al
    Selective Tetramodal Bladder Preservation Therapy Incorporating Induction Chemoradiotherapy and Consolidative Partial Cystectomy with Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer: Oncological and Functional Outcomes of 107 Patients.
    BJU Int. 2019 Feb 27. doi: 10.1111/bju.14736.
    Abstract    

    Abstract available

  146. TARIQ A, Khan SR, Vela I, Williams ED, et al
    Assessment of bladder cancer patients and carers use of internet, social media and quality of available patient centric online resources: A systematic review.
    BJU Int. 2019 Feb 24. doi: 10.1111/bju.14720.
    Abstract    

    Abstract available

  147. SOLOWAY MS
    Postoperative intravesical chemotherapy has an important role in reducing subsequent bladder tumours - why is it not routine?
    BJU Int. 2018;122:525-526.
    Abstract    



  148. CHU AT, Holt SK, Wright JL, Ramos JD, et al
    Delays in radical cystectomy for muscle-invasive bladder cancer.
    Cancer. 2019 Mar 6. doi: 10.1002/cncr.32048.
    Abstract    

    Abstract available

  149. MASIC S, Smaldone MC
    Treatment delays for muscle-invasive bladder cancer.
    Cancer. 2019 Mar 6. doi: 10.1002/cncr.32047.
    Abstract    



  150. WANG Z, Cao D, Qi Z, Pang Y, et al
    Retinoic acid-related orphan receptor C regulates proliferation, glycolysis, and chemoresistance via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer.
    Cancer Res. 2019 Feb 26. pii: 0008-5472.CAN-18-3842.
    Abstract    

    Abstract available

  151. AVGERIS M, Tsilimantou A, Levis PK, Rampias T, et al
    Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
    Carcinogenesis. 2019 Feb 27. pii: 5366409. doi: 10.1093.
    Abstract    

    Abstract available

  152. VANTAKU V, Dong J, Ambati CR, Perera D, et al
    sMulti-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in Bladder Cancer.
    Clin Cancer Res. 2019 Mar 7. pii: 1078-0432.CCR-18-1515.
    Abstract    

    Abstract available

  153. KISS B, van den Berg NS, Ertsey R, McKenna K, et al
    CD47-targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer.
    Clin Cancer Res. 2019 Mar 19. pii: 1078-0432.CCR-18-3267.
    Abstract    

    Abstract available

  154. MUN DH, Kimura S, Shariat SF, Abufaraj M, et al
    The impact of gender on oncologic outcomes of bladder cancer.
    Curr Opin Urol. 2019 Mar 6. doi: 10.1097/MOU.0000000000000606.
    Abstract    

    Abstract available

  155. EULITT PJ, Bjurlin MA, Milowsky MI
    Perioperative systemic therapy for bladder cancer.
    Curr Opin Urol. 2019 Mar 6. doi: 10.1097/MOU.0000000000000600.
    Abstract    

    Abstract available

  156. SMELSER WW, Woolbright BL, Taylor JA 3rd
    Molecular subtyping of bladder cancer: current trends and future directions in 2019.
    Curr Opin Urol. 2019 Mar 6. doi: 10.1097/MOU.0000000000000599.
    Abstract    

    Abstract available

  157. PHAM A, Ballas LK
    Trimodality therapy for bladder cancer: modern management and future directions.
    Curr Opin Urol. 2019 Mar 6. doi: 10.1097/MOU.0000000000000601.
    Abstract    

    Abstract available

  158. BHAT A, Ritch CR
    Urinary biomarkers in bladder cancer: where do we stand?
    Curr Opin Urol. 2019 Mar 6. doi: 10.1097/MOU.0000000000000605.
    Abstract    

    Abstract available

  159. JANISCH F, Shariat SF, Schernhammer E, Rink M, et al
    The interaction of gender and smoking on bladder cancer risks.
    Curr Opin Urol. 2019 Mar 14. doi: 10.1097/MOU.0000000000000602.
    Abstract    

    Abstract available

  160. WITJES JA
    Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
    Eur Urol. 2019 Feb 25. pii: S0302-2838(19)30163.
    Abstract    



  161. PICHLER R, Heidegger I
    Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.11.055.
    Eur Urol. 2019 Feb 22. pii: S0302-2838(19)30159.
    Abstract    



  162. LI R, Spiess PE, Gilbert SM, Necchi A, et al
    Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30174.
    Abstract    

    Abstract available

  163. NARAYAN VM, Lim AH, Dinney CPN
    Re: Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2019 Mar 1. pii: S0302-2838(19)30165.
    Abstract    



  164. MONTORSI F, Gandaglia G
    Re: Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, et al. Port-site Metastases After Robot-assisted Radical Cystectomy: Is There a Publication Bias? Eur Urol 2018;73:641-2.
    Eur Urol. 2019;75:e31.
    Abstract    



  165. CAMPI R, Roupret M
    Re: Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-institutional Cohort Study.
    Eur Urol. 2019 Mar 14. pii: S0302-2838(19)30187.
    Abstract    



  166. GAKIS G
    Re: Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
    Eur Urol. 2019 Mar 13. pii: S0302-2838(19)30181.
    Abstract    



  167. HUANG Z, Zhang M, Chen G, Wang W, et al
    Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression.
    Int J Oncol. 2019 Feb 27. doi: 10.3892/ijo.2019.4729.
    Abstract    

    Abstract available

  168. LEE A, Lee HJ, Huang HH, Ho H, et al
    Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13913.
    Abstract    

    Abstract available

  169. ZACHOS I
    Editorial Comment to Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13929.
    Abstract    



  170. TEKE K, Yilmaz H, Uslubas AK, Akpinar G, et al
    Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette-Guerin on precancerous lesions of bladder in a rat model.
    Int Urol Nephrol. 2018;50:1417-1425.
    Abstract    

    Abstract available

  171. ZEWIN TS, El-Assmy A, Harraz AM, Bazeed M, et al
    Efficacy and safety of low-intensity shock wave therapy in penile rehabilitation post nerve-sparing radical cystoprostatectomy: a randomized controlled trial.
    Int Urol Nephrol. 2018;50:2007-2014.
    Abstract    

    Abstract available

  172. ZHANG S
    Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer: Time to Change Clinical Practice?
    J Clin Oncol. 2019 Feb 27:JCO1801864. doi: 10.1200/JCO.18.01864.
    Abstract    



  173. WINTERS BR, Wen L, Holt SK, Dash A, et al
    Does the diagnosis of bladder cancer lead to higher rates of smoking cessation? Findings from the Medicare Health Outcomes Survey.
    J Urol. 2019 Mar 5:101097JU0000000000000206. doi: 10.1097/JU.0000000000000206.
    Abstract    

    Abstract available

  174. LEO MC, Gilbert SM, Wendel CS, Krouse RS, et al
    Development of a goal elicitation measure to support bladder cancer patients' choice about urinary diversion.
    J Urol. 2019 Mar 5:101097JU0000000000000203. doi: 10.1097/JU.0000000000000203.
    Abstract    

    Abstract available

  175. CHANG SS
    Re: Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients with Recurrent Bladder Cancer.
    J Urol. 2019 Mar 13:10109701JU000055464194059.
    Abstract    



  176. CHANG SS
    Re: Partial Bladder Boost Using Lipiodol Marking during Image-Guided Radiotherapy for Bladder Cancer.
    J Urol. 2019 Mar 13:101097JU0000000000000218. doi: 10.1097/JU.0000000000000218.
    Abstract    



  177. GRIEBLING TL
    Re: Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives Concerning the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
    J Urol. 2019 Mar 13:10109701JU00005546361960937.
    Abstract    



  178. GRIEBLING TL
    Re: Outcomes of Radiosensitisation in Elderly Patients with Advanced Bladder Cancer.
    J Urol. 2019 Mar 13:10109701JU00005546347386712.
    Abstract    



  179. GRIEBLING TL
    Re: Real-World Effectiveness of Chemotherapy in Elderly Patients with Metastatic Bladder Cancer in the United States.
    J Urol. 2019 Mar 13:10109701JU0000554635814908.
    Abstract    



  180. FEUERSTEIN MA
    Editorial Comment.
    J Urol. 2018;200:290.
    Abstract    



  181. PATEL S, Cookson MS
    Editorial Comment.
    J Urol. 2018;200:290-291.
    Abstract    



  182. ZARGAR-SHOSHTARI K, Sexton WJ
    Re: Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence: B. Kiss, M. A. Furrer, P. Y. Wuethrich, F. C. Burkhard, G. N. Thalmann and B. Roth J Urol 2017;198:1263-1268.
    J Urol. 2018;200:457-458.
    Abstract    



  183. LIU JY, Zeng QH, Cao PG, Xie D, et al
    SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.
    Oncogene. 2018;37:3937-3952.
    Abstract    

    Abstract available

  184. LIU Q, Gheorghiu L, Drumm M, Clayman R, et al
    PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
    Oncogene. 2018;37:2793-2805.
    Abstract    

    Abstract available

  185. ZHUO Z, Song Z, Ma Z, Zhang Y, et al
    Chlorophyllin e6mediated photodynamic therapy inhibits proliferation and induces apoptosis in human bladder cancer cells.
    Oncol Rep. 2019 Feb 14. doi: 10.3892/or.2019.7013.
    Abstract    

    Abstract available

  186. HO JN, Byun SS, Lee SE, Youn JI, et al
    Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatinresistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway.
    Oncol Rep. 2019 Feb 11. doi: 10.3892/or.2019.7005.
    Abstract    

    Abstract available

  187. CHENG H, Hao Y, Gao Y, He Y, et al
    PLCepsilon promotes urinary bladder cancer cells proliferation through STAT3/LDHA pathwaymediated glycolysis.
    Oncol Rep. 2019 Mar 13. doi: 10.3892/or.2019.7056.
    Abstract    

    Abstract available

  188. SEKINO Y, Sakamoto N, Ishikawa A, Honma R, et al
    Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Oncol Rep. 2019 Feb 28. doi: 10.3892/or.2019.7039.
    Abstract    

    Abstract available

  189. HORI S, Miyake M, Tatsumi Y, Morizawa Y, et al
    Intravesical treatment of chemotherapeutic agents sensitizes bacillus CalmetteGuerin by the modulation of the tumor immune environment.
    Oncol Rep. 2019;41:1863-1874.
    Abstract    

    Abstract available

  190. CARRION A, Diaz F, Raventos C, Lozano F, et al
    Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years.
    Urol Int. 2019 Mar 7:1-7. doi: 10.1159/000496802.
    Abstract    

    Abstract available

  191. LV S, Wang W, Wang H, Zhu Y, et al
    PPARgamma activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway.
    BMC Cancer. 2019;19:204.
    Abstract    

    Abstract available

  192. PANG K, Zhang Z, Hao L, Shi Z, et al
    The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells.
    BMC Cancer. 2019;19:225.
    Abstract    

    Abstract available

  193. SIMON M, Bosset PO, Rouanne M, Benhamou S, et al
    Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.
    PLoS One. 2019;14:e0211721.
    Abstract    

    Abstract available

  194. BAUSCH K, Roth E, Heinz S, Horst D, et al
    Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer.
    PLoS One. 2019;14:e0213549.
    Abstract    

    Abstract available

  195. LU DL, Ren ZJ, Zhang Q, Ren PW, et al
    Meta-analysis of the association between the inflammatory potential of diet and urologic cancer risk.
    PLoS One. 2018;13:e0204845.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;